Establishment and application of drug use evaluation criteria for aspirin enteric-coated tablets

Published on May. 29, 2024Total Views: 536 times Total Downloads: 271 times Download Mobile

Author: LIN Meimei ¹ ZHANG Jingv ² ZHENG Caiyun ¹ CHEN Yan ¹ GAO Yanling ¹ CHEN Shicai ³  ZHANG Jinhua ⁴

Affiliation: 1. Department of Pharmacy, Fuqing Hospital Affiliated to Fujian Medical University, Fuqing 350300, Fujian Province, China 2. Department of Pharmacy, The People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou 350004, China 3. Department of Pharmacy, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China 4. Department of Pharmacy, Fujian Maternity and Child Health Care Hospital, Fuzhou 350001, China

Keywords: Aspirin enteric-coated tablets Drug use evaluation Expert consultation Rational drug use

DOI: 10.12173/j.issn.1005-0698.202312012

Reference: LIN Meimei, ZHANG Jing, ZHENG Caiyun, CHEN Yan, GAO Yanling, CHEN Shicai,ZHANG Jinhua.Establishment and application of drug use evaluation criteria for aspirin entericcoated tablets[J].Yaowu Liuxingbingxue Zazhi,2024, 33(5):489-499.DOI: 10.12173/j.issn.1005-0698.202312012.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish the drug use evaluation (DUE) criteria for aspirin enteric-coated tablets and provide a reference for the rationally clinical application of aspirin enteric-coated tablets.

Methods DUE criteria for aspirin enteric-coated tablets were established from three aspects of indications, medications and medication results with reference to drug instructions of aspirin enteric-coated tablets, related guidelines, expert consensus and literature, and through Delphi method. A retrospective analysis was conducted to evaluate the medical records of patients who took aspirin enteric-coated tablets from January 2021 to June 2022 in Fuqing Hospital affiliated to Fujian Medical University.

Results A total of 1 071 medical records were included. 683 cases fully met the DUE criteria, with a rational rate of 63.77%. Irrational drug use mainly included inappropriate indications (6.26%), off-label drug use without approval (28.48%), contraindications (1.03%), inappropriate usage and dosage (1.68%), drug interactions with potential clinical significance (0.65%) and other inappropriate drug use (2.71%).

Conclusion The established DUE standard for aspirin enteric-coated tablets has strong scientific practicability and feasibility. The irrational rate of aspirin enteric-coated tablets in this hospital is high. Corresponding intervention measures should be formulated to ensure the safety of clinical medication.

Full-text

Please download the PDF version to read the full text: download

References

1.刘杰. 阿司匹林药理作用的研究新进展[J].中国中医药现代远程教育, 2009, 7(1): 86-87. [Liu J. New research progress of aspirin pharmacological effects[J]. Modern Distance Education of Chinese Medicine, 2009, 7(1): 86-87.] DOI: 10.3969/j.issn.1672-2779.2009.01.059.

2.王聪, 史琛, 张玉. 甲磺酸阿美替尼药物利用评价标准的建立及应用[J]. 中国药师, 2022, 25(8): 1402-1405.[Wang C, Shi C, Zhang Y. Establishment and application of medication use evaluation criteria for almonertinib mesilate[J]. China Pharmacist, 2022, 25(8): 1402-1405.] DOI: 10.19962/j.cnki.issn1008-049X.2022.08.018.

3.中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南（2020）[J]. 中华妇产科杂志, 2020, 55(4): 227-238. DOI: 10.3760/cma.j.cn112141-20200114-00039.

4.中华医学会儿科学分会心血管学组, 中华医学会儿科学分会风湿学组, 中华医学会儿科学分会免疫学组, 等. 川崎病诊断和急性期治疗专家共识[J]. 中华儿科杂志, 2022, 60(1): 6-13. DOI: 10.3760/cma.j.cn112140-20211018-00879.

5.国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志（电子版）, 2018, 10(6): 1-130. DOI: 10.12037/YXQY. 2018.06-01.

6.Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2022, 145(3): e4-e17. DOI: 10.1161/CIR.0000000000001039.

7.中华医学会外科学分会血管外科学组. 下肢动脉硬化闭塞症诊治指南[J]. 中华普通外科学文献（电子版）, 2016, 10(1): 1-18. DOI: 10.3877/cma.j.issn.1674-0793. 2016.01.001.

8.中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理手册（2022）[J]. 中华内科杂志, 2022, 61(7): 717-748. DOI: 10.3760/cma.j.cn112138-20220509-00350.

9.王树洪, 田银, 王瑞烈. 无原发疾病创伤性脾破裂行脾切除术后血小板计数的变化情况[J]. 当代医学, 2020, 26(36): 129-131. [Wang SH, Tian Y, Wang RL.Changes of platelet count after splenectomy with traumatic rupture of the spleen without primary disease[J]. Contemporary Medicine, 2020, 26(36): 129-131.] DOI: 10. 3969/j.issn.1009-4393.2020.36.050.

10.中国医师协会血管外科医师分会静脉学组. 常见静脉疾病诊治规范（2022年版）[J]. 中华血管外科杂志, 2022, 7(1): 12-29. DOI: 10.3760/cma.j.cn101411-20211218-00102.

11.中华医学会血液学分会白血病淋巴瘤学组.原发性血小板增多症诊断与治疗中国专家共识（2016年版）[J].中华血液学杂志, 2016, 37(10): 833-836. DOI: 10.3760/cma.j.issn.0253-2727.2016.10.001.

12.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

13.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南（2019）[J]. 中华心血管病杂志, 2019, 47(10): 766-783. DOI: 10.3760/cma.j.issn.0253-3758.2019.10.003.

14.中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南（2019）[J]. 中华急诊医学杂志, 2019, 28(4): 421-428. DOI: 10.3760/cma.j.issn.1671-0282.2019.04.003.

15.中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南（2016）[J]. 中华心血管病杂志, 2016, 44(5): 382-400. DOI: 10.3760/cma.j.issn.0253-3758.2016.05.006.

16.张宾, 郝呈泉. 长期服用阿司匹林的不良反应及防治措施[J]. 中外医学研究, 2011, 9(12): 40. [Zhang B, Hao CC. The adverse reactions and prevention measures of long-term use of aspirin[J]. Chinese and Foreign Medical Research, 2011, 9(12): 40.] DOI: 10.3969/j.issn.1674-6805.2011.12.032.

17.《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36): 2861-2888. DOI: 10.3760/cma.j.issn.0376-2491.2018.36.002.

18.李素琼. 利拉鲁肽药物利用评价标准的构建和应用 [D]. 昆明: 昆明医科大学, 2022.

19.甘念, 罗敏, 吴丽芬. 基于德尔菲法与层次分析法构建儿科门诊护理质量评价体系[J]. 护理实践与研究, 2021, 18(10): 1573-1576. [Gan N, Luo M, Wu LF. Constructing an evaluation system of pediatric outpatient nursing quality based on Delphi method and analytic hierarchy process method[J]. Nursing Practice and Research, 2021, 18(10): 1573-1576.] DOI: 10.3969/j.issn.1672-9676.2021.10.045.

20.陈翠, 郝建玲, 陶红, 等. 德尔菲专家咨询法在构建个人防护技巧核心指标核查表中的应用[J]. 解放军医院管理杂志, 2020, 27(6): 507-510, 515. [Chen C. Hao JL, Tao H, et al. Application of Delphi method in core indicators checklist construction of personal protective skills[J]. Hospital Administration Journal of Chinese People's Liberation Army, 2020, 27(6): 507-510, 515.] DOI: 10.16770/J.cnki.1008-9985.2020.06.003.

21.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

22.刘凌云. 《医院处方点评管理规范(试行)》执行中的难点及对判定标准的探讨[J]. 中国医院用药评价与分析, 2016, 16(1): 107-110. [Liu LY. Difficulties in implementation of Management Standards for Hospital Prescription Evaluation (Trial) and exploration of evaluation criteria[J]. Evaluation and Analysis of Drug Use in Chinese Hospitals, 2016, 16(1): 107-110.] DOI: 10.14009/j.issn. 1672-2124.2016.01.038.

23.刘艳杰, 李琳, 吴烨青. 《医院处方点评管理规范(试行)》执行中存在问题的思考[J]. 中国药业, 2013, 22(8): 70-71. [Liu YJ, Li L, Wu YQ. Thingking on the problems in implementation of Management Standards for Hospital Prescription Evaluation (Trial) [J]. China Pharm, 2013, 22(8): 70-71.] DOI: 10.3969/j.issn.1006-4931.2013.08.042.

24.Stanworth SJ, Dowling K, Curry N, et al. Haematological management of major haemorrhage: a British Society for Haematology guideline[J]. Br J Haematol, 2022, 198(4): 654-667. DOI: 10.1111/bjh.18275.

25.2019阿司匹林在心血管疾病一级预防中的应用中国专家共识写作组. 2019阿司匹林在心血管疾病一级预防中的应用中国专家共识[J]. 中华心血管病杂志（网络版）, 2019, 2(1): 1-5. DOI: 10.3760/cma.j.issn.2096- 1588.2019.1000020.

26.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation, 2019, 140(11): e596-e646. DOI: 10.1161/CIR.0000000000000678.

27.中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南基层版[J]. 中华心血管病杂志, 2023, 51(4): 343-363. DOI: 10.3760/cma.j.cn112148-20230106-00014.

28.Wang X, Wang H, Zheng Q, et al. Outcomes associated with 50 mg/d and 100 mg/d aspirin for the prevention and management of cardiovascular disease in chinese elderly: single-center interim analysis of a multicenter, prospective, observational study[J]. Int J Gen Med, 2022, 15: 7089-7100. DOI: 10.2147/IJGM.S384375.

29.中华人民共和国国家卫生健康委员会. 流行性感冒诊疗方案（2020年版）[J]. 全科医学临床与教育, 2020, 18(12): 1059-1063. DOI: 10.13558/j.cnki.issn1672-3686. 2020.012.002.

30.张秋霞, 王玉玲. 小剂量肠溶阿司匹林致肾损害16例分析[J]. 药物不良反应杂志, 2004, 6(2): 82-84. [Zhang QX, Wang YL. 16 cases of renal damage caused by low-dose enteric-coated aspirin[J]. Journal of Adverse Drug Reaction, 2004, 6(2): 82-84.] DOI: 10.3969/j.issn.1008- 5734.2004.02.003.

31.Tanrikulu AM, Ozben B, Koc M, et al. Aspirin resistance in patients with chronic renal failure[J]. J Nephrol, 2011, 24(5): 636-46. DOI: 10.5301/JN.2011.6259.

32.孙云. 阿司匹林与布洛芬相互作用对阿司匹林心血管保护作用的影响[J]. 中国保健营养, 2016, 26(30): 41-41, 42. [Sun Y. The effect of aspirin and ibuprofen on the cardiovascular protective effect of aspirin[J]. China Health Care ＆ Nutrition, 2016, 26(30): 41-41, 42.] DOI: 10.3969/j.issn.1004-7484.2016.30.051.

33.孙海燕. 基于FDA不良事件数据库阿司匹林相关痛风和高尿酸血症不良事件分析[J]. 药学研究, 2022, 41(12): 838-840. [Sun HY. Analysis of aspirin related gout and hyperuricaemia adverse events based on FDA adverse event database[J]. Journal of pharmaceutical Research, 2022, 41(12): 838-840.] DOI: 10.13506/j.cnki.jpr.2022.12.014.

34.谢成钧. 1例服用阿司匹林致痛风发作的案例分析[J]. 世界最新医学信息文摘, 2017, 17(68): 184. [Xie CJ. A case study of gout attack induced by aspirin[J]. World Latest Medicine Information, 2017, 17(68): 184.] DOI: 10.19613/j.cnki.1671-3141.2017.68.096.

35.周琳, 石磊, 石焱. 小剂量阿司匹林对老年糖尿病患者血尿酸水平影响[J]. 临床军医杂志, 2019, 47(10): 1132-1133. [Zhou L, Shi L, Shi Y. Effect of low-dose aspirin on blood uric acid in elderly diabetic patients[J]. Clinical Journal of Medical Officers, 2019, 47(10): 1132-1133.] DOI: 10.16680/j.1671-3826.2019.10.42.

36.杜忠东, 谢利剑, 刘世平, 等. 阿司匹林在川崎病治疗中的儿科专家共识[J]. 中国当代儿科杂志, 2022, 24(6): 597-603. [Du ZD, Xie LJ, Liu SP, et al. Pediatric consensus on aspirin in the treatment of Kawasaki disease[J]. Chineses Journal of Contemporary Pediatrics, 2022, 24(6): 597-603.] DOI: 10.7499/j.issn.1008-8830. 2203190.